GLP-1 & compounded medication availability in West Virginia (2026)

West Virginia earned its place on the early research list for two reasons: its pharmacy regulator was one of the first in the country to publish a hard position on compounded semaglutide, and a persistent rumor claims the state blocks telehealth weight-loss prescribing altogether. The first is real and cited below. The second is false. We read the section’s text and its amendment history first-hand, and this page says so with the receipts.

Conditional state

Availability facts last reviewed: November 16, 2026

What reaches a West Virginia address

Availability of all ten OrderlyMeds product lines in West Virginia, with typical delivery times and notes
Product lineAvailable in West Virginia?Typical deliveryNotes
GLP-1 (compounded semaglutide) Yes 8–10 business days Patient-specific prescriptions, base form only. The state’s 2023 statement is cited below.
GLP-1/GIP (compounded tirzepatide) Yes 8–10 business days Same footing as the row above; the statement names semaglutide, the principles carry.
NAD+ Yes 8–10 business days No West Virginia-specific finding for this line.
Sermorelin Yes 8–10 business days Ships normally; nothing state-specific surfaced in this research pass.
Glutathione No N/A Not in the OrderlyMeds formulary in any state.
BPC-157 Yes 8–10 business days Compounded injectable; the federal record below travels with it.
TB-500 Yes 8–10 business days Compounded injectable; see its own section.
KPV No N/A Not carried anywhere, under our injectables-only house rule.
Epitalon Yes 8–10 business days Compounded injectable; record in its section.
MOTS-c Yes 8–10 business days Compounded injectable whose federal record stands apart, below.

Both No rows are formulary facts that would be true in any state. They render anyway; a row that disappears when the answer is No defeats the point of a page like this. Reviewed November 16, 2026.

BPC-157 through MOTS-c: the West Virginia file

West Virginia’s regulators have published positions on compounded semaglutide, cited in the next section, but nothing peptide-specific that this research pass could locate. So the five sections below carry exactly the federal record every page in this family carries: four lines in the OrderlyMeds catalog as compounded injectables, KPV in no state, each line’s facts stated on its own.

BPC-157 in West Virginia

Dispensed into West Virginia as a compounded injectable on a patient-specific prescription. The record that comes with it:

FDA’s evaluation of bulk drug substances for compounding under section 503A placed BPC-157 in Category 2, and BPC-157 has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense BPC-157 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

TB-500 in West Virginia

In the catalog for West Virginia as an injectable, same patient-specific basis. Its federal facts:

FDA’s evaluation of bulk drug substances for compounding under section 503A placed TB-500 (thymosin beta-4 fragment) in Category 2, and TB-500 (thymosin beta-4 fragment) has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense TB-500 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

KPV in West Virginia

Not dispensed by OrderlyMeds in West Virginia or any other state; our peptide lines are injectables and KPV is not among them.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed KPV in Category 2, and KPV has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense KPV pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

Epitalon in West Virginia

Ships here as a compounded injectable. Read its record before deciding anything:

FDA’s evaluation of bulk drug substances for compounding under section 503A placed Epitalon in Category 2, and Epitalon has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense Epitalon pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

MOTS-c in West Virginia

Available to West Virginia patients as a compounded injectable. Its federal paper trail is its own, different from the four above, and it reads as follows:

FDA has evaluated MOTS-c as a bulk drug substance nominated for the section 503A bulks list and proposed that neither MOTS-c (free base) nor MOTS-c acetate be included on it, and MOTS-c has no FDA-approved indication. MOTS-c was formerly listed in Category 2 of FDA’s interim compounding policy, and it is no longer on that active list as of FDA’s April 22, 2026 update, because the nomination was withdrawn by the nominator. FDA’s record for the substance notes a potential immunogenicity concern by certain routes and no clinical data in humans, and FDA presented MOTS-c to its Pharmacy Compounding Advisory Committee in July 2026. Under the enforcement-discretion policy HHS published October 30, 2026 at 91 FR 68526, HHS does not intend to act against a state-licensed pharmacy, Federal facility, or licensed physician compounding MOTS-c under section 503A, limited to subcutaneous or intramuscular administration, under a valid patient-specific prescription, and subject to the policy’s other conditions, while rulemaking on the bulks list is pending. That policy does not add MOTS-c to the bulks list and does not make it an FDA-approved drug. Sources: FDA — bulk drug substances that may present significant safety risks (Category 2 and withdrawn nominations) · FDA — PCAC briefing document, July 23–24, 2026 (MOTS-c proposals, points 7–8) · HHS — 91 FR 68526, enforcement-discretion policy for 503A peptide compounding.

What West Virginia’s pharmacy regulators say about compounded medications

Two real conditions, one early warning shot, and one myth worth retiring. That is the West Virginia file in full. Each item below links the state’s own text.

In an April 2023 statement, the West Virginia Board of Pharmacy warned that compounding pharmacies generally may not compound semaglutide as an essentially-a-copy of a commercially available product, that no salt form of semaglutide may be used in a compounded drug product, that research-use-only material may not be used for compounding in any circumstance, and that non-conforming compounding may lead to enforcement action by FDA and the board. Source: West Virginia Board of Pharmacy — Statement Concerning Semaglutide Compounding.

Out-of-state pharmacies dispensing into West Virginia must register with the board under W. Va. Code §30-5-24, and under the board’s rule effective July 1, 2026, a nonresident pharmacy registers in the same manner as a mail-order pharmacy and its pharmacist-in-charge (or a designated pharmacist) must hold a West Virginia pharmacist license (15 CSR 6). Sources: W. Va. Code §30-5-24 · 15 CSR 6 — Mail-Order and Non-Resident Pharmacies.

West Virginia’s telemedicine statute permits establishing the physician-patient relationship through real-time video or real-time audio-only encounters — while treatment, including issuing a prescription, based solely on an online questionnaire does not constitute an acceptable standard of care (W. Va. Code §30-3-13a). Source: W. Va. Code §30-3-13a.

The often-repeated claim that West Virginia bans telemedicine prescribing of weight-loss drugs is not in the law: §30-3-13a’s drug-specific limits cover Schedule II controlled substances and certain pain and abortion-related prescribing, the word “weight” appears nowhere in the section, and the state’s pharmacy code expressly accepts a relationship established “through telemedicine practice approved by the appropriate practitioner board” (W. Va. Code §30-5-4). Sources: W. Va. Code §30-3-13a · W. Va. Code §30-5-4.

For out-of-state practitioners using West Virginia’s interstate telehealth registration, board rules require an established patient to have an in-person visit within 12 months of the initial telemedicine service — a requirement the treating practitioner may suspend case by case — under W. Va. Code §30-1-26(b)(4). Source: W. Va. Code §30-1-26.

Put together: an OrderlyMeds order reaches West Virginia through a registered pharmacy, on a patient-specific prescription written after a real-time telehealth evaluation, using base semaglutide, never a salt form, never research-use-only material. That is the shape the 2023 statement demands, and it is the shape the order already has. One honest footnote: the 2023 statement lives on the board’s own website rather than a .gov domain, and we cite it there because the board’s site is the primary source, not a summary of one.

West Virginia availability FAQs

Is compounded semaglutide available in West Virginia?

Yes. OrderlyMeds ships compounded semaglutide to West Virginia addresses under patient-specific prescriptions, base form and never salt forms, from pharmacies registered with the state. The state’s own 2023 compounding statement is cited in the regulator section. New customers start at $74/month for the first two months.

Doesn’t West Virginia block telehealth weight-loss prescriptions?

No. We checked the text and its amendment history first-hand, and West Virginia’s telemedicine rules contain no weight-loss prescribing restriction and never have. The state’s drug-specific telehealth limits cover other categories entirely. The citation is in the regulator section above.

Can I get BPC-157 or other research peptides shipped to West Virginia?

BPC-157, TB-500, Epitalon and MOTS-c ship to West Virginia as compounded injectables under a patient-specific prescription; KPV does not, because we compound these lines as injectables only. Each line’s own federal record is stated in its section above.

How long does delivery to West Virginia take?

Our published window is 8–10 business days from signup, the same for West Virginia as for every state we ship to.

Keep exploring

Ready when you are

See if you’re eligible

Compounded semaglutide from $74/month for your first 2 months — provider visit, medication, syringes, and shipping all included, at the same price for every dose. No membership fees.

Check eligibility

Secure. Private. No commitment

The OrderlyMeds eligibility check on a phone